Brazil Says Chinese Vaccine Trial can Resume

“After evaluating the new data presented by the sponsor, Anvisa understands that it has sufficient reasons to allow the resumption of vaccination,” the agency said.

RIO DE JANEIRO, BRAZIL - Brazill health regulator Anvisa on Wednesday allowed resumption of late-stage clinical trials for China’s Sinovac COVID-19 vaccine, which had been suspended due to the death of a study subject that was registered in São Paulo as a suicide.

Brazil . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?